Alan Kelly is the Vice President, Head of Alofisel Manufacturing across Takedas cell therapy network of sites in Europe, Japan and the US. Prior to this, Alan was Head of Vaccines Engineering, responsible for the vaccines capital investment portfolio for Takeda. Alan spent his formative years at Takeda's Irish plants in Bray and GC before relocating to Zurich in 2016 as Global Head of Operational Excellence for Takeda’s Global Manufacturing and Supply Organization. During his time as Head of Operational Excellence he initiated the AGILE Transformation Program, launching the program during its inception in 2016. He has over 20 years pharma manufacturing experience across multiple geographies and multiple technologies. He is a Biochemist, lean six sigma black belt and a Qualified Person.